Serum fibronectin levels in malignant and benign endometrial diseases

Dimitar Mitev; Sergei Slavov; Georgi Dimitrov; Irena Shikova; Julieta Hristova; Stoyan Kostov; Angel Yordanov

doi:10.5114/pm.2024.143419

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

3/2024
vol. 23

Send email

Copy url:

abstract:

Original paper

Serum fibronectin levels in malignant and benign endometrial diseases

Dimitar Mitev

¹

,

Sergei Slavov

¹

,

Georgi Dimitrov

¹

,

Irena Shikova

¹

,

Julieta Hristova

²

,

Stoyan Kostov

^{3, 4}

,

Angel Yordanov

⁵

University Hospital of Obstetrics and Gynecology “Maichin dom” – Sofia, Medical University – Sofia, Bulgaria
Department of Clinical Laboratory and Clinical Pharmacology – University Hospital “Alexandrovska”, Medical University – Sofia, Bulgaria
Department of Gynecology, Hospital “Saint Anna”, Medical University – “Prof. Dr. Paraskev Stoyanov”, Varna, Bulgaria
Research Institute, Medical University Pleven, Pleven, Bulgaria
Department of Gynecologic Oncology, Medical University Pleven, Pleven, Bulgaria

Menopause Rev 2024; 23(3): 140-144

DOI: https://doi.org/10.5114/pm.2024.143419

Online publish date: 2024/10/14

View full text Get citation

PlumX metrics:

Introduction
Endometrial cancer is currently the most common malignancy of the female reproductive system. The significance of the disease is determined by the search for additional biomarkers with the aim to optimize earlier diagnosis and to help for timely treatment. The objective of this study was to assess the serum levels of fibronectin (FN) in patients with malignant endometrial pathology and to compare them with patients with benign pathology and healthy women.

Material and methods
We analyzed serum FN levels in women with malignant and benign pathology of the endometrium. Blood serum samples were collected from 100 patients – 50 diagnosed with endometrial cancer and 50 with confirmed endometrial polyps. In addition, 50 control subjects were tested. Fibronectin levels were measured by enzyme-linked immunosorbent assay (ELISA) according to the protocol

Results
Statistical analysis was performed and the results demonstrated statistical significances (p = 0.008) of FN levels in the group with endometrial cancer (mean 482.73, median 409.12 µg/ml) compared to the control group (mean 346.86, median 258.87 µg/ml), but no significant difference in FN levels was observed between the group with endometrial malignancy and the group with benign pathology of the endometrium. In addition, in the cancer group FN levels did not show any significant differences depending on the histologic type.

Conclusions
The serum FN concentration can be used as an additional tumor marker for gynecological malignancies and can be a potential diagnostic and prognostic marker for malignant endometrial pathology as well as for other gynecological malignancies.

keywords:

Serum fibronectin levels in malignant and benign endometrial diseases

Dimitar Mitev 1 , Sergei Slavov 1 , Georgi Dimitrov 1 , Irena Shikova 1 , Julieta Hristova 2 , Stoyan Kostov 3, 4 , Angel Yordanov 5

endometrial cancer, fibronectin, polyps, benign pathology of the endometrium, malignant pathology of the endometrium

Dimitar Mitev

¹

,

Sergei Slavov

¹

,

Georgi Dimitrov

¹

,

Irena Shikova

¹

,

Julieta Hristova

²

,

Stoyan Kostov

^{3, 4}

,

Angel Yordanov

⁵